Kamada Ltd., a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced the expansion of its plasma collection operations with the opening of a third plasma collection center.
The new 11,100 square foot center in San Antonio, TX, is operated by Kamada’s wholly owned subsidiary, Kamada Plasma, and is planned to support close to 50 donor beds with an estimated total collection capacity of approximately 50,000 liters annually.
“We are extremely pleased to announce the opening of our new state-of-the-art plasma collection center in San Antonio,” said Amir London, Chief Executive Officer of Kamada. “The opening of this center will expand the collection capacity of specialty plasma, such as Anti-Rabies and Anti-D, for our internal use beyond our existing sites in Beaumont and Houston, TX. The collected specialty plasma will support our increasing demand for hyper-immune plasma and is expected to lower our raw material costs. The new center will also collect normal source plasma to be sold to third parties. We are especially grateful for the skilled and experienced team of plasma collection experts we have appointed to lead the establishment and operations of our new center.”
The new center is expected to contribute annual revenues of $8 million to $10 million in sales of normal source plasma at its full capacity.
Kamada intends to submit approval applications for the new site to the U.S. FDA and the European Medicines Agency during the second half of 2025, and the Company currently anticipates approval decisions from both agencies within 9-12 months of the submissions.